Literature DB >> 8057070

Continuation of warfarin-nafcillin interaction during dicloxacillin therapy.

A T Taylor1, D C Pritchard, A O Goldstein, J L Fletcher.   

Abstract

Interactions between warfarin and penicillins have been infrequently reported. A case report of a single patient who experienced the effects of a warfarin-nafcillin interaction as well as a warfarin-dicloxacillin interaction is presented. Clinical effects of this interaction were documented primarily through changes in prothrombin time (PT) and the need for higher warfarin dosing. While the patient received nafcillin, warfarin doses were increased to as much as 4.5 times the previous amounts needed to provide adequate anticoagulation. During dicloxacillin therapy, warfarin doses were gradually decreased, but stabilized to a maintenance dose higher than the patient's pre-nafcillin dose. The dicloxacillin-warfarin interaction appears similar to that noted during nafcillin-warfarin combination.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8057070

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  4 in total

1.  A probable clinically significant interaction between warfarin and cloxacillin: three case reports.

Authors:  Hossein Khalili; Naemeh Nikvarz; Farhad Najmeddin; Simin Dashti-Khavidaki
Journal:  Eur J Clin Pharmacol       Date:  2012-09-04       Impact factor: 2.953

2.  Significant drug-drug interaction between warfarin and nafcillin.

Authors:  Cynthia A King; Kathleen M Babcock; Rhianna J Godios; Benjamin S King
Journal:  Ther Adv Drug Saf       Date:  2018-08-31

Review 3.  Clinically important drug interactions with anticoagulants. An update.

Authors:  S Harder; P Thürmann
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

4.  Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams.

Authors:  Mathieu S Bolhuis; Prashant N Panday; Arianna D Pranger; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Pharmaceutics       Date:  2011-11-18       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.